The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis.

ABSTRACT:

Background

Schizophrenia is a chronic and debilitating neuropsychiatric disorder that often requires long-term pharmacotherapy to manage symptoms and prevent relapse. Cariprazine is a potent dopamine D₃ and D₂ receptor partial agonist that is FDA-approved in the US for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adults; the recommended dose range is 1.5-6 mg/d.

Methods

To further characterize the long-term safety of cariprazine, data from two 48-week open-label, flexible-dose extension studies were pooled for post hoc analyses. Outcomes were evaluated in the pooled safety population (patients who received ≥1 dose of cariprazine during an open-label extension period); findings were summarized using des

SUBMITTER: Nasrallah HA 

PROVIDER: S-EPMC5571492 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature